ClinicalTrials.gg
CompletedNCT02871778CLEAN-PCDUpdated Dec 16, 2021Results posted

Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia

A Phase 2 interventional study of VX-371 and Hypertonic Saline in Primary Ciliary Dyskinesia, sponsored by Parion Sciences. Completed at 34 sites in 8 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-12-16.

Sponsored by Parion Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Ciliary Motility Disorders with a site in United States — 9 open to participants now, 11 under way, none of them phase 3. Ciliary Motility Disorders · United States.

Started
2016
with 1 other
Phase 2
Only one
of the 28
Registered
10th of 28
by date

Among the 28 studies in Ciliary Motility Disorders with a site in United States, this one is one of 2 that started in 2016, is the only one in phase 2, and was the 10th registered.

Ciliary Motility Disorders

79 studies on the registry are indexed under Ciliary Motility Disorders; 26 are open to participants now.

Browse Ciliary Motility Disorders studies →

Open to participants now

9 of the 28 studies in Ciliary Motility Disorders with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Ciliary Motility Disorders studies recruiting now, 14 (70%) set no upper age limit and 3 (15%) stop at 75 or younger; 17 take children under 18; 7 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Ciliary Motility Disorders with a site in United States, or all of them as a file.
02

Study summary

To evaluate the safety and efficacy of treatment with VX-371 with and without ivacaftor, and the effect of VX-371 with and without ivacaftor on quality of life (QOL) in subjects with primary ciliary dyskinesia (PCD).

03

Conditions studied

  • Primary Ciliary Dyskinesia
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject must have evidence supportive of a PCD diagnosis.
  • Subjects with percent predicted of ≥40 to \<90 percentage points
  • Non-smoker for at least 90 days prior to the Screening Visit and less than a 5 pack-year lifetime history of smoking
  • Stable regimen of medications and chest physiotherapy for the 28 days prior to Day 1
  • If currently using daily inhaled HS, must be able to discontinue its use for the duration of the study.
  • If taking daily chronic or chronic cycling antibiotics, has been on a consistent regimen for at least 4 months prior to the Screening Visit.
  • Clinically stable (as deemed by the investigator) for at least 14 days prior to the Screening Visit
  • Female subjects of must have a negative serum pregnancy test at the Screening Visit. Subjects of childbearing potential and who are sexually active must meet the requirements.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of CF based on results of sweat chloride or nasal potential difference (NPD) tests or presence of 2 CF-causing mutations in CFTR gene.
  • History of any organ transplantation or lung resection or chest wall surgery.
  • Significant congenital heart defects, other than a laterality defect, at the discretion of the investigator
  • Diagnosis of Cri du chat syndrome (chromosome 5p deletion syndrome).
  • Inability to withhold short-acting bronchodilator use for 4 hours prior to clinic visit and long-acting bronchodilator use the night before the first and last clinic visit of each treatment period.
  • Use of diuretics (including amiloride) or renin-angiotensin antihypertensive drugs
  • Symptoms of acute upper or lower respiratory tract infection, acute pulmonary exacerbation, or treatment or was treated with systemic antibiotics for ear or sinus disease within 28 days before Day 1 (topical otic antibiotics allowed).
  • History of significant intolerance to inhaled HS
  • Pregnant and/or nursing females
  • Any laboratory abnormalities
  • History of chronic B. cepacia complex or M. abscessus or M. avium
  • Surgery that required general anesthesia and hospitalization within 3 months of Day 1

Additional Exclusion Criteria for Part B:

  • In addition to the exclusion criteria above, subjects who participate in Part B and meet any of the following exclusion criteria will not be eligible to continue into Part B
  • Unable to swallow tablets.
  • Concomitant use of strong or moderate inhibitors or inducers of cytochrome P450 (CYP) 3A, including consumption of certain herbal medications (e.g., St. John's Wort), and grapefruit/grapefruit juice.
  • Known to ivacaftor.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
123 participants (actual)

Study arms

  • Experimental
    Part A: VX-371 in Hypertonic Saline (HS), Then HS

    Participants received 85 microgram (mcg) VX-371 diluted in 3 milliliter (mL) 4.2 percent (%) HS twice daily through oral nebulized inhalation from Day 1 through Day 29 in treatment period 1 followed by a 28 day washout period (from Day 29 through Day 56) and then received 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2.

    Drug: Hypertonic Saline · Drug: VX-371 + HS

  • Experimental
    Part A: HS, Then VX-371 in HS

    Participants received 3 mL 4.2% HS through oral nebulized inhalation twice daily from Day 1 through Day 29 in treatment period 1 followed by a 28 day washout period (from Day 29 through Day 56) and then received 85 mcg VX-371 diluted in 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2.

    Drug: Hypertonic Saline · Drug: VX-371 + HS

  • Experimental
    Part A: VX-371, Then Placebo

    Participants received 85 mcg VX-371 diluted in 3 mL 0.17% Saline (placebo) through oral nebulized inhalation twice daily from Day 1 through Day 29 in treatment period 1 followed by a 28 day washout period (from Day 29 through Day 56) and then received 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2.

    Drug: VX-371 · Drug: Placebo (0.17% saline)

  • Experimental
    Part A: Placebo, Then VX-371

    Participants received 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily from Day 1 through Day 29 in treatment period 1 followed by a 28 day washout period (from Day 29 through Day 56) and then received 85 mcg VX-371 diluted in 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2.

    Drug: VX-371 · Drug: Placebo (0.17% saline)

  • Experimental
    Part B: VX-371 in HS + Ivacaftor

    Participants who were on 85 mcg VX-371 diluted in 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2 continued their inhaled study drug regimen from Treatment Period 2 and also received ivacaftor 150 mg tablet twice daily for 28 days (from Day 85 through Day 113) in treatment period 3.

    Drug: VX-371 + HS · Drug: Ivacaftor

  • Experimental
    Part B: HS + Ivacaftor

    Participants who were on 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2 continued their inhaled study drug regimen from Treatment Period 2 and also received ivacaftor 150 mg tablet twice daily for 28 days (from Day 85 through Day 113) in treatment period 3.

    Drug: Hypertonic Saline · Drug: Ivacaftor

  • Experimental
    Part B: VX-371 + Ivacaftor

    Participants who were on 85 mcg VX-371 diluted in 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2 continued their inhaled study drug regimen from Treatment Period 2 and also received ivacaftor 150 mg tablet twice daily for 28 days (from Day 85 through Day 113) in treatment period 3.

    Drug: VX-371 · Drug: Ivacaftor

  • Placebo comparator
    Part B: Placebo + Ivacaftor

    Participants who were on 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2 continued their inhaled study drug regimen from Treatment Period 2 and also received ivacaftor 150 mg tablet twice daily for 28 days (from Day 85 through Day 113) in treatment period 3.

    Drug: Placebo (0.17% saline) · Drug: Ivacaftor

Interventions

06

What researchers measure

Primary outcomes

  1. Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs included abnormal clinically significant findings for spirometry, clinical laboratory parameters, standard 12-lead electrocardiograms (ECGs), vital signs and pulse oximetry examinations. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 84 days that were absent before treatment or that worsened relative to pretreatment state. TEAEs included both serious and non-serious TEAEs.

    Time frame: Part A: From first dose of study drug up 84 days

  2. Part B: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs included abnormal clinically significant findings for spirometry, clinical laboratory parameters, standard 12-lead electrocardiograms (ECGs), vital signs and pulse oximetry examinations. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. TEAEs included both serious and non-serious TEAEs.

    Time frame: Part B: Day 85 up to 28 days after last dose of study drug (56 days)

  3. Part A: Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 29

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. The study baseline is defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of study drug in the study.

    Time frame: Part A: Study Baseline, Day 29 of each treatment period

  4. Part B: Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 29

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. The study baseline is defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of study drug in the study.

    Time frame: Study Baseline, Day 29 of Part B

  5. Part B: Absolute Change From Part B Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 29

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Part B baseline was defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of ivacaftor in Part B and after the last dose in Period 2.

    Time frame: Part B Baseline, Day 29 of Part B

Secondary outcomes

  1. Part A: Change From Study Baseline in Quality of Life-Primary Ciliary Dyskinesia (QOL-PCD) (Adult Version) Lower Respiratory Symptoms Domain Score at Day 29

    QOL- PCD adult version has following 10 domains: lower respiratory symptoms, emotional functioning, treatment burden, role, social functioning, vitality, health perception, upper respiratory symptoms, physical functioning and hearing symptoms. The total numbers of items in the lower respiratory symptoms domain are 6 in the questionnaire for adults. All items are scored using a 4-point Likert scale. Scaled score calculated as: \[Sum of scores - (n\*1)\] / \[(n\*4) - (n\*1)\]\*100. Where 'n' is the number of questions in domain. The total score range is from 0-100, where higher score indicates greater improvement. Change from study baseline \>0 indicated improvement. The study baseline is defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of study drug in the study.

    Time frame: Study Baseline, Day 29 of Part A

  2. Part B: Change From Study Baseline in Quality of Life-Primary Ciliary Dyskinesia (QOL-PCD) (Adult Version) Lower Respiratory Symptoms Domain Score at Day 29

    QOL- PCD adult version has following 10 domains: lower respiratory symptoms, emotional functioning, treatment burden, role, social functioning, vitality, health perception, upper respiratory symptoms, physical functioning and hearing symptoms. The total numbers of items in the lower respiratory symptoms domain are 6 in the questionnaire for adults. All items are scored using a 4-point Likert scale. Scaled score calculated as: \[Sum of scores - (n\*1)\] / \[(n\*4) - (n\*1)\]\*100. Where 'n' is the number of questions in domain. The total score range is from 0-100, where higher score indicates greater improvement. Change from study baseline \>0 indicated improvement. The study baseline is defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of study drug in the study.

    Time frame: Study Baseline, Day 29 of Part B

  3. Part B: Change From Part B Baseline in Quality of Life-Primary Ciliary Dyskinesia (QOL-PCD) (Adult Version) Lower Respiratory Symptoms Domain Score at Day 29

    QOL- PCD adult version has following 10 domains: lower respiratory symptoms, emotional functioning, treatment burden, role, social functioning, vitality, health perception, upper respiratory symptoms, physical functioning and hearing symptoms. The total numbers of items in the lower respiratory symptoms domain are 6 in the questionnaire for adults. All items are scored using a 4-point Likert scale. Scaled score calculated as: \[Sum of scores - (n\*1)\] / \[(n\*4) - (n\*1)\]\*100. Where 'n' is the number of questions in domain. The total score range is from 0-100, where higher score indicates greater improvement. Change from Part B baseline \>0 indicated improvement. Part B baseline was defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of ivacaftor in Part B and after the last dose in Period 2.

    Time frame: Part B Baseline, Day 29 of Part B

  4. Part A: Change From Study Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score for Participants Aged Greater Than or Equals to (>=) 16 Years at Day 29

    SGRQ measured health-related quality of life among participants with respiratory diseases. It is a 40 items questionnaire grouped into three domains (Symptoms, Activity, and Impacts). Total scores range from 0 to 100. Higher score reflected worse quality of life. The study baseline is defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of study drug in the study.

    Time frame: Study Baseline, Day 29 of Part A

  5. Part B: Change From Study Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score for Participants Aged >=16 Years at Day 29

    SGRQ measured health-related quality of life among participants with respiratory diseases. It is a 40 items questionnaire grouped into three domains (Symptoms, Activity, and Impacts). Total scores range from 0 to 100. Higher score reflected worse quality of life. The study baseline is defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of study drug in the study.

    Time frame: Study Baseline, Day 29 of Part B

  6. Part B: Change From Part B Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score for Participants Aged >=16 Years at Day 29

    SGRQ measured health-related quality of life among participants with respiratory diseases. It is a 40 items questionnaire grouped into three domains (Symptoms, Activity, and Impacts). Total scores range from 0 to 100. Higher score reflected worse quality of life. Part B baseline was defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of ivacaftor in Part B and after the last dose in Period 2.

    Time frame: Part B Baseline, Day 29 of Part B

07

Results

Posted Dec 16, 2021

Participant flow

Part A: Treatment Period 1
Participant flow — Part A: Treatment Period 1
MilestonePart A: VX-371 in Hypertonic Saline (HS), Then HSPart A: HS, Then VX-371 in HSPart A: VX-371, Then PlaceboPart A: Placebo, Then VX-371Part B: VX-371 in HS + IvacaftorPart B: HS + IvacaftorPart B: VX-371 + IvacaftorPart B: Placebo + Ivacaftor
Started434121180000
Safety analysis set444021180000
Completed403718160000
Not completed34320000
Withdrew: Adverse event11100000
Withdrew: Withdrawal of consent (not due to adverse event)22020000
Withdrew: Noncompliant with study drug00100000
Withdrew: Other withdrawal criteria met00100000
Withdrew: Wrong drug shipment01000000
Part A: Treatment Period 2
Participant flow — Part A: Treatment Period 2
MilestonePart A: VX-371 in Hypertonic Saline (HS), Then HSPart A: HS, Then VX-371 in HSPart A: VX-371, Then PlaceboPart A: Placebo, Then VX-371Part B: VX-371 in HS + IvacaftorPart B: HS + IvacaftorPart B: VX-371 + IvacaftorPart B: Placebo + Ivacaftor
Started403718160000
Safety analysis set403718160000
Completed373517150000
Not completed32110000
Withdrew: Adverse event22000000
Withdrew: Lost to follow-up00010000
Withdrew: Non-compliant with study drug10100000
Part B: Treatment Period 3
Participant flow — Part B: Treatment Period 3
MilestonePart A: VX-371 in Hypertonic Saline (HS), Then HSPart A: HS, Then VX-371 in HSPart A: VX-371, Then PlaceboPart A: Placebo, Then VX-371Part B: VX-371 in HS + IvacaftorPart B: HS + IvacaftorPart B: VX-371 + IvacaftorPart B: Placebo + Ivacaftor
Started00001127712
Safety analysis set00001127712
Completed00001026612
Not completed00001110
Withdrew: Adverse event00001110

Outcome measures

PrimaryPart A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs included abnormal clinically significant findings for spirometry, clinical laboratory parameters, standard 12-lead electrocardiograms (ECGs), vital signs and pulse oximetry examinations. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 84 days that were absent before treatment or that worsened relative to pretreatment state. TEAEs included both serious and non-serious TEAEs.

Time frame:
Part A: From first dose of study drug up 84 days
Reported as:
Count of participants · Participants
Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsPart A: VX-371 in HSPart A: HSPart A: VX-371Part A: Placebo
Participants with TEAEs52462223
Participants with Serious TEAEs1111
PrimaryPart B: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs included abnormal clinically significant findings for spirometry, clinical laboratory parameters, standard 12-lead electrocardiograms (ECGs), vital signs and pulse oximetry examinations. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. TEAEs included both serious and non-serious TEAEs.

Time frame:
Part B: Day 85 up to 28 days after last dose of study drug (56 days)
Reported as:
Count of participants · Participants
Part B: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsPart B: VX-371 in HS + IVAPart B: HS + IVAPart B: VX-371 + IVAPart B: Placebo + IVA
Participants with TEAEs51759
Participants with Serious TEAEs0010
PrimaryPart A: Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 29

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. The study baseline is defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of study drug in the study.

Time frame:
Part A: Study Baseline, Day 29 of each treatment period
Reported as:
Least squares mean · Percentage of predicted FEV1
Part A: Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 29
Percentage of predicted FEV1Part A: VX-371 in HSPart A: HSPart A: VX-371Part A: Placebo
Part A: Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 290.989 ± 0.7097-0.531 ± 0.7202-0.491 ± 1.0736-1.329 ± 1.0730
Statistical analysis
  • Part A: VX-371 in HS vs Part A: HS · Mixed-effects Model · p = 0.0437 · Least square (ls) mean difference: 1.519 · 95% CI 0.044 to 2.995
  • Part A: HS vs Part A: VX-371 · Mixed-effects Model · p = 0.9755 · Ls mean difference: 0.040 · 95% CI -2.509 to 2.589
  • Part A: VX-371 in HS vs Part A: Placebo · Mixed-effects Model · p = 0.0731 · Ls mean difference: 2.318 · 95% CI -0.22 to 4.856
  • Part A: HS vs Part A: Placebo · Mixed-effects Model · p = 0.5373 · Ls mean difference: 0.799 · 95% CI -1.751 to 3.348
  • Part A: VX-371 vs Part A: Placebo · Mixed-effects Model · p = 0.453 · Ls mean difference: 0.838 · 95% CI -1.368 to 3.045
PrimaryPart B: Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 29

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. The study baseline is defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of study drug in the study.

Time frame:
Study Baseline, Day 29 of Part B
Reported as:
Least squares mean · Percentage of predicted FEV1
Part B: Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 29
Percentage of predicted FEV1Part B: VX-371 in HS + IvacaftorPart B: HS + IvacaftorPart B: VX-371 + IvacaftorPart B: Placebo + Ivacaftor
Part B: Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 294.721 ± 1.93141.722 ± 1.1976-0.592 ± 2.5011-0.965 ± 1.8388
PrimaryPart B: Absolute Change From Part B Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 29

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Part B baseline was defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of ivacaftor in Part B and after the last dose in Period 2.

Time frame:
Part B Baseline, Day 29 of Part B
Reported as:
Least squares mean · Percentage of predicted FEV1
Part B: Absolute Change From Part B Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 29
Percentage of predicted FEV1Part B: VX-371 in HS + IvacaftorPart B: HS + IvacaftorPart B: VX-371 + IvacaftorPart B: Placebo + Ivacaftor
Part B: Absolute Change From Part B Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 292.528 ± 1.86331.678 ± 1.1414-1.018 ± 2.3797-2.040 ± 1.7427
SecondaryPart A: Change From Study Baseline in Quality of Life-Primary Ciliary Dyskinesia (QOL-PCD) (Adult Version) Lower Respiratory Symptoms Domain Score at Day 29

QOL- PCD adult version has following 10 domains: lower respiratory symptoms, emotional functioning, treatment burden, role, social functioning, vitality, health perception, upper respiratory symptoms, physical functioning and hearing symptoms. The total numbers of items in the lower respiratory symptoms domain are 6 in the questionnaire for adults. All items are scored using a 4-point Likert scale. Scaled score calculated as: \[Sum of scores - (n\*1)\] / \[(n\*4) - (n\*1)\]\*100. Where 'n' is the number of questions in domain. The total score range is from 0-100, where higher score indicates greater improvement. Change from study baseline \>0 indicated improvement. The study baseline is defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of study drug in the study.

Time frame:
Study Baseline, Day 29 of Part A
Reported as:
Mean · score on a scale
Part A: Change From Study Baseline in Quality of Life-Primary Ciliary Dyskinesia (QOL-PCD) (Adult Version) Lower Respiratory Symptoms Domain Score at Day 29
score on a scalePart A: VX-371 in HSPart A: HSPart A: VX-371Part A: Placebo
Part A: Change From Study Baseline in Quality of Life-Primary Ciliary Dyskinesia (QOL-PCD) (Adult Version) Lower Respiratory Symptoms Domain Score at Day 294.23 ± 18.0763.58 ± 16.7150.98 ± 12.9157.04 ± 16.728
SecondaryPart B: Change From Study Baseline in Quality of Life-Primary Ciliary Dyskinesia (QOL-PCD) (Adult Version) Lower Respiratory Symptoms Domain Score at Day 29

QOL- PCD adult version has following 10 domains: lower respiratory symptoms, emotional functioning, treatment burden, role, social functioning, vitality, health perception, upper respiratory symptoms, physical functioning and hearing symptoms. The total numbers of items in the lower respiratory symptoms domain are 6 in the questionnaire for adults. All items are scored using a 4-point Likert scale. Scaled score calculated as: \[Sum of scores - (n\*1)\] / \[(n\*4) - (n\*1)\]\*100. Where 'n' is the number of questions in domain. The total score range is from 0-100, where higher score indicates greater improvement. Change from study baseline \>0 indicated improvement. The study baseline is defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of study drug in the study.

Time frame:
Study Baseline, Day 29 of Part B
Reported as:
Mean · score on a scale
Part B: Change From Study Baseline in Quality of Life-Primary Ciliary Dyskinesia (QOL-PCD) (Adult Version) Lower Respiratory Symptoms Domain Score at Day 29
score on a scalePart B: VX-371 in HS + IvacaftorPart B: HS + IvacaftorPart B: VX-371 + IvacaftorPart B: Placebo + Ivacaftor
Part B: Change From Study Baseline in Quality of Life-Primary Ciliary Dyskinesia (QOL-PCD) (Adult Version) Lower Respiratory Symptoms Domain Score at Day 2916.67 ± 14.4871.39 ± 17.1537.41 ± 3.208-5.56 ± 23.307
SecondaryPart B: Change From Part B Baseline in Quality of Life-Primary Ciliary Dyskinesia (QOL-PCD) (Adult Version) Lower Respiratory Symptoms Domain Score at Day 29

QOL- PCD adult version has following 10 domains: lower respiratory symptoms, emotional functioning, treatment burden, role, social functioning, vitality, health perception, upper respiratory symptoms, physical functioning and hearing symptoms. The total numbers of items in the lower respiratory symptoms domain are 6 in the questionnaire for adults. All items are scored using a 4-point Likert scale. Scaled score calculated as: \[Sum of scores - (n\*1)\] / \[(n\*4) - (n\*1)\]\*100. Where 'n' is the number of questions in domain. The total score range is from 0-100, where higher score indicates greater improvement. Change from Part B baseline \>0 indicated improvement. Part B baseline was defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of ivacaftor in Part B and after the last dose in Period 2.

Time frame:
Part B Baseline, Day 29 of Part B
Reported as:
Mean · score on a scale
Part B: Change From Part B Baseline in Quality of Life-Primary Ciliary Dyskinesia (QOL-PCD) (Adult Version) Lower Respiratory Symptoms Domain Score at Day 29
score on a scalePart B: VX-371 in HS + IvacaftorPart B: HS + IvacaftorPart B: VX-371 + IvacaftorPart B: Placebo + Ivacaftor
Part B: Change From Part B Baseline in Quality of Life-Primary Ciliary Dyskinesia (QOL-PCD) (Adult Version) Lower Respiratory Symptoms Domain Score at Day 2911.11 ± 15.7131.39 ± 19.9285.56 ± 16.667-7.41 ± 10.344
SecondaryPart A: Change From Study Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score for Participants Aged Greater Than or Equals to (>=) 16 Years at Day 29

SGRQ measured health-related quality of life among participants with respiratory diseases. It is a 40 items questionnaire grouped into three domains (Symptoms, Activity, and Impacts). Total scores range from 0 to 100. Higher score reflected worse quality of life. The study baseline is defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of study drug in the study.

Time frame:
Study Baseline, Day 29 of Part A
Reported as:
Mean · score on a scale
Part A: Change From Study Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score for Participants Aged Greater Than or Equals to (>=) 16 Years at Day 29
score on a scalePart A: VX-371 in HSPart A: HSPart A: VX-371Part A: Placebo
Part A: Change From Study Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score for Participants Aged Greater Than or Equals to (>=) 16 Years at Day 29-1.28 ± 8.452-2.17 ± 6.4621.54 ± 8.576-1.52 ± 9.082
SecondaryPart B: Change From Study Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score for Participants Aged >=16 Years at Day 29

SGRQ measured health-related quality of life among participants with respiratory diseases. It is a 40 items questionnaire grouped into three domains (Symptoms, Activity, and Impacts). Total scores range from 0 to 100. Higher score reflected worse quality of life. The study baseline is defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of study drug in the study.

Time frame:
Study Baseline, Day 29 of Part B
Reported as:
Mean · score on a scale
Part B: Change From Study Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score for Participants Aged >=16 Years at Day 29
score on a scalePart B: VX-371 in HS + IvacaftorPart B: HS + IvacaftorPart B: VX-371 + IvacaftorPart B: Placebo + Ivacaftor
Part B: Change From Study Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score for Participants Aged >=16 Years at Day 29-1.69 ± 7.442-6.87 ± 6.5710.78 ± 5.8794.52 ± 16.995
SecondaryPart B: Change From Part B Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score for Participants Aged >=16 Years at Day 29

SGRQ measured health-related quality of life among participants with respiratory diseases. It is a 40 items questionnaire grouped into three domains (Symptoms, Activity, and Impacts). Total scores range from 0 to 100. Higher score reflected worse quality of life. Part B baseline was defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of ivacaftor in Part B and after the last dose in Period 2.

Time frame:
Part B Baseline, Day 29 of Part B
Reported as:
Mean · score on a scale
Part B: Change From Part B Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score for Participants Aged >=16 Years at Day 29
score on a scalePart B: VX-371 in HS + IvacaftorPart B: HS + IvacaftorPart B: VX-371 + IvacaftorPart B: Placebo + Ivacaftor
Part B: Change From Part B Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score for Participants Aged >=16 Years at Day 29-3.90 ± 4.331-2.64 ± 6.5750.97 ± 7.5613.19 ± 11.649

Adverse events

Collected over Part A: From first dose of study drug up to 84 days; Part B: Day 85 up to 28 days after last dose of study drug (56 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: VX-371 in HS0/81 (0%)1/81 (1.2%)40/81 (49.4%)
Part A: HS0/80 (0%)1/80 (1.3%)27/80 (33.8%)
Part A: VX-3710/37 (0%)1/37 (2.7%)12/37 (32.4%)
Part A: Placebo0/36 (0%)1/36 (2.8%)16/36 (44.4%)
Part B: VX-371 in HS + Ivacaftor0/11 (0%)0/11 (0%)5/11 (45.5%)
Part B: HS + Ivacaftor0/27 (0%)0/27 (0%)15/27 (55.6%)
Part B: VX-371 + Ivacaftor0/7 (0%)1/7 (14.3%)4/7 (57.1%)
Part B: Placebo + Ivacaftor0/12 (0%)0/12 (0%)9/12 (75%)
Most frequent serious events
Most frequent serious events
EventPart A: VX-371 in HSPart A: HSPart A: VX-371Part A: PlaceboPart B: VX-371 in HS + IvacaftorPart B: HS + IvacaftorPart B: VX-371 + IvacaftorPart B: Placebo + Ivacaftor
PneumoniaInfections and infestations0/810/800/370/360/110/271/70/12
HaemoptysisRespiratory, thoracic and mediastinal disorders0/810/800/371/360/110/270/70/12
Lung disorderRespiratory, thoracic and mediastinal disorders0/811/801/370/360/110/270/70/12
BronchiectasisRespiratory, thoracic and mediastinal disorders1/810/800/370/360/110/270/70/12
Most frequent other events
Showing 10 of 43
Most frequent other events
EventPart A: VX-371 in HSPart A: HSPart A: VX-371Part A: PlaceboPart B: VX-371 in HS + IvacaftorPart B: HS + IvacaftorPart B: VX-371 + IvacaftorPart B: Placebo + Ivacaftor
Oropharyngeal painRespiratory, thoracic and mediastinal disorders8/813/803/370/360/112/272/71/12
CoughRespiratory, thoracic and mediastinal disorders11/818/804/373/363/112/270/71/12
HeadacheNervous system disorders8/817/802/376/363/114/270/73/12
DiarrhoeaGastrointestinal disorders0/810/800/370/360/115/271/70/12
FatigueGeneral disorders2/814/802/372/362/111/271/70/12
Lipase increasedInvestigations0/810/800/370/360/110/270/72/12
Weight decreasedInvestigations0/810/800/370/360/110/271/70/12
DysphoniaRespiratory, thoracic and mediastinal disorders0/810/800/370/360/110/271/70/12
Eye pruritusEye disorders0/810/800/370/360/110/271/70/12
Vision blurredEye disorders0/810/800/370/360/110/271/70/12

Baseline characteristics

Part A Full analysis set (FAS) included all randomized participants who received at least 1 dose of study drug in Part A and had a confirmed diagnosis of primary ciliary dyskinesia (PCD).

Age, Continuous
Age, Continuous(years)Part A: VX-371 in HS, Then HSPart A: HS, Then VX-371 in HSPart A: VX-371, Then PlaceboPart A: Placebo, Then VX-371Total
Mean29.19 ± 10.86127.98 ± 13.10427.62 ± 16.63324.33 ± 12.86627.80 ± 12.954
Sex: Female, Male
Sex: Female, Male(Participants)Part A: VX-371 in HS, Then HSPart A: HS, Then VX-371 in HSPart A: VX-371, Then PlaceboPart A: Placebo, Then VX-371Total
Female2924151078
Male14176845
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: VX-371 in HS, Then HSPart A: HS, Then VX-371 in HSPart A: VX-371, Then PlaceboPart A: Placebo, Then VX-371Total
Hispanic or Latino23207
Not Hispanic or Latino41371818114
Unknown or Not Reported01102
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A: VX-371 in HS, Then HSPart A: HS, Then VX-371 in HSPart A: VX-371, Then PlaceboPart A: Placebo, Then VX-371Total
American Indian or Alaska Native00000
Asian13138
Native Hawaiian or Other Pacific Islander00000
Black or African American21115
White39361714106
More than one race00000
Unknown or Not Reported11204
08

Study locations

34 sites
  • Birmingham, Alabama, United States
  • Palo Alto, California, United States
  • Aurora, Colorado, United States
  • Washington, District of Columbia, United States
  • Miami, Florida, United States
  • Tampa, Florida, United States
  • Chicago, Illinois, United States
  • Indianapolis, Indiana, United States
  • Iowa City, Iowa, United States
  • Kansas City, Kansas, United States
  • Boston, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Minneapolis, Minnesota, United States
  • Kansas City, Missouri, United States
  • Saint Louis, Missouri, United States
  • New York, New York, United States
  • Chapel Hill, North Carolina, United States
  • Cleveland, Ohio, United States
  • Philadelphia, Pennsylvania, United States
  • Columbia, South Carolina, United States
  • Seattle, Washington, United States
  • Toronto, Ontario, Canada
  • Montreal, Quebec, Canada
  • Copenhagen, Denmark
  • Munster, North Rhine-Westphalia, Germany
  • Hannover, Germany
  • Heidelberg, Germany
  • Pisa, Italy
  • Amsterdam, Netherlands
  • Rotterdam, Netherlands
  • Rabka-Zdroj, Poland
  • Cambridge, United Kingdom
  • London, United Kingdom
  • Southampton, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2016 to primary completion in Nov 2018, 27 months.

Results were first posted in Dec 2021, 3 years after primary completion. A results delay was requested in Nov 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2016
First posted
Aug 18, 2016
StartActual
Aug 2016
Primary completionActual
Nov 20, 2018
CompletionActual
Nov 20, 2018
Results delay requested
Nov 20, 2019
Results first posted
Dec 16, 2021
Last update
Dec 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02871778
Lead sponsor
Parion Sciences
Responsible party
Sponsor
First posted
Aug 18, 2016
Start date
Aug 2016
Primary completion
Nov 20, 2018
Completion
Nov 20, 2018
Results posted
Dec 16, 2021
Last update
Dec 16, 2021

Study contacts

Karl Donn
study chair · Parion Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Idrevloride · Ivacaftor

Start the discussion